All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61]
PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71]
PRINCIPLE, 2021 1.65 [0.03; 83.12]
1.18 [0.12 ; 11.55 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, PATCH Cohort 1 (Amaravadi), 2021, PRINCIPLE, 2021 3 0% 1,644 moderate not evaluable hospitalization or deathdetailed results Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92]
0.91 [0.43 ; 1.92 ] Hinks (ATOMIC2), 2021 1 0% 292 NA not evaluable A EFFACER PCR-negative (end of follow-up)detailed results Hinks (ATOMIC2), 2021 0.91 [0.57; 1.46]
0.91 [0.57 ; 1.46 ] Hinks (ATOMIC2), 2021 1 0% 295 NA not evaluable clinical deteriorationdetailed results PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68]
0.51 [0.07 ; 3.68 ] PATCH Cohort 1 (Amaravadi), 2021 1 0% 28 NA not evaluable clinical improvementdetailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [0.95 ; 1.23 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable clinical improvement (time to event analysis only)detailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [0.95 ; 1.23 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable hospitalizationdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76]
Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96]
PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93]
PRINCIPLE, 2021 0.94 [0.50; 1.75]
Roozbeh, 2020 0.23 [0.02; 2.21]
0.86 [0.58 ; 1.29 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Hinks (ATOMIC2), 2021, PATCH Cohort 1 (Amaravadi), 2021, PRINCIPLE, 2021, Roozbeh, 2020 5 0% 1,995 moderate not evaluable mechanical ventilationdetailed results PRINCIPLE, 2021 0.50 [0.10; 2.60]
0.50 [0.10 ; 2.60 ] PRINCIPLE, 2021 1 0% 1,121 NA not evaluable ICU admissiondetailed results PRINCIPLE, 2021 0.76 [0.18; 3.18]
0.76 [0.18 ; 3.18 ] PRINCIPLE, 2021 1 0% 1,120 NA not evaluable adverse eventsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85]
178.20 [73.71 ; 430.85 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1 0% 353 NA not evaluable 0.2 500.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-05 00:19 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
